Interim Results from STOMP Study of SIGA’s Tecovirimat in Treatment of Mpox Announced
Interim analysis shows that tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate clade II mpox Study stopped enrolling patients in all study arms Results affirm tecovirimat’s strong safety profile …